Navigate the landscape
in our Pharma R&D
Annual Review 2022
Ian Lloyd introduces the 30th Annual Pharma R&D Review 2022
Watch Ian Lloyd set the scene for this year’s momentous Pharma R&D Annual Review 2022. This year’s review is packed with Pharma R&D intelligence that will help you chart a course for 2022 and beyond.
The Pharma R&D Annual Review 2022:
30th Anniversary Infographic & Whitepaper
For our 30th yearly edition, we take you on a travel themed journey into the industry as we look at the ever-evolving Pharma landscape.
Your guide, Senior Director of Pharmaprojects and intrepid explorer, Ian Lloyd.
You can now listen to the Pharma R&D Review 2022.
Let the story unfold in this engaging audio version of all the key drug development insights over the past year.
Chart your own course and navigate the landscape at your pace listening to key chapters when you want.
NAS Supplements
Learn more about our suite of solutions providing the industry’s most comprehensive, reliable, and up-to-date global R&D intelligence.
Navigating the Landscape
30th Annual Pharma R&D Review 2022 Webinar
Available to watch on demand
Ian Lloyd, Senior Director of Pharmaprojects & Alex Shimmings, Executive Editor – Commercial/R&D
Based on his findings in the Annual Pharma R&D Review, Ian Lloyd & Alex Shimmings discuss clinical phase trends, top companies by pipeline size and number of drugs in development, top therapies and therapeutic categories, and more.
Now available on demand - catch up now
Pharmaprojects & Biomedtracker – solutions better together
Optimize your portfolio and licensing strategy with end-to-end intelligence for the global drug development pipeline.